Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Alterations in immune function are associated with liver enzyme elevation in HIV and HCV co-infection after commencement of combination antiretroviral therapy.

Cameron BA, Emerson CR, Workman C, Kelly MD, Lloyd AR, Post JJ.

J Clin Immunol. 2011 Dec;31(6):1079-83. doi: 10.1007/s10875-011-9587-6. Epub 2011 Sep 20.

PMID:
21932111
2.

Transient liver injury associated with the early recovery of HCV-specific T-cell responses and HCV rebound in HIV-1/HCV coinfected patients undergoing highly active antiretroviral therapy.

Kang F, Chen W, Zhang X, Nie W, Fu J, Xu X, Zhao P, Zhang X, Li W, Wang FS, Zhang Z, Zhao M.

J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):135-42. doi: 10.1097/QAI.0b013e3182752d20.

PMID:
23075912
4.

Preservation of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses despite global loss of CD4+ T cells in HCV/HIV coinfection.

Morishima C, Shuhart MC, Yoshihara CS, Paschal DM, Silva MA, Thomassen LV, Emerson SS, Gretch DR.

J Infect Dis. 2007 Aug 15;196(4):577-86. Epub 2007 Jun 28.

PMID:
17624844
5.

Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.

Kovari H, Ledergerber B, Battegay M, Rauch A, Hirschel B, Foguena AK, Vernazza P, Bernasconi E, Mueller NJ, Weber R.

Clin Infect Dis. 2010 Feb 15;50(4):502-11. doi: 10.1086/649922.

PMID:
20085465
6.

Impact of HIV on host-virus interactions during early hepatitis C virus infection.

Danta M, Semmo N, Fabris P, Brown D, Pybus OG, Sabin CA, Bhagani S, Emery VC, Dusheiko GM, Klenerman P.

J Infect Dis. 2008 Jun 1;197(11):1558-66. doi: 10.1086/587843.

PMID:
18419344
8.

Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.

De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, Poggio A, Pagano G, Tositti G, Cadeo G, Macor A, Toti M, D'Arminio Monforte A; Italian Cohort Naive Antiretrovirals Study Group.

Arch Intern Med. 2002 Oct 14;162(18):2125-32.

PMID:
12374521
9.

Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease.

Santin M, Mestre M, Shaw E, Barbera MJ, Casanova A, Niubo J, Bolao F, Podzamczer D, Gudiol F.

Eur J Clin Microbiol Infect Dis. 2008 Jan;27(1):65-73.

PMID:
17938979
10.

Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients.

Torti C, Lapadula G, Uccelli MC, Quiros-Roldan E, Regazzi M, Ladisa N, Micheli V, Orani A, Patroni A, Caputo SL, Tirelli V, Di Giambenedetto S, Cologni G, Costarelli S, Gargiulo F, Manca N, Carosi G; RADAR Study Group of MASTER Cohort.

Int J Antimicrob Agents. 2007 Feb;29(2):185-90. Epub 2006 Oct 2.

PMID:
17011754
11.

Liver enzymes elevation after HAART in HIV-HCV co-infection.

Servin-Abad L, Molina E, Baracco G, Arosemena L, Regev A, Jeffers L, Schiff E.

J Viral Hepat. 2005 Jul;12(4):429-34.

PMID:
15985015
12.

Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy.

Núñez M, Ríos P, Martín-Carbonero L, Pérez-Olmeda M, González-Lahoz J, Soriano V.

J Acquir Immune Defic Syndr. 2002 May 1;30(1):65-8.

PMID:
12048364
13.

Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection.

Asmuth DM, Busch MP, Laycock ME, Mohr BA, Kalish LA, van der Horst CM; Viral Activation Transfusion Study (VATS) Group.

Antiviral Res. 2004 Aug;63(2):123-31.

PMID:
15302141
15.

HIV and hepatitis C coinfection.

Matthews GV, Dore GJ.

J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 1):1000-8. doi: 10.1111/j.1440-1746.2008.05489.x. Review.

PMID:
18707597
16.

Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy.

Torre D, Tambini R, Cadario F, Barbarini G, Moroni M, Basilico C.

Clin Infect Dis. 2001 Nov 1;33(9):1579-85. Epub 2001 Oct 4.

PMID:
11588701
17.

Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation.

Meraviglia P, Schiavini M, Castagna A, Viganò P, Bini T, Landonio S, Danise A, Moioli MC, Angeli E, Bongiovanni M, Hasson H, Duca P, Cargnel A.

HIV Med. 2004 Sep;5(5):334-43.

18.

Understanding human immunodeficiency virus type 1 and hepatitis C virus coinfection.

Tan YJ, Lim SG, Hong W.

Curr HIV Res. 2006 Jan;4(1):21-30. Review.

PMID:
16454708
19.

Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?

Cicconi P, Cozzi-Lepri A, Phillips A, Puoti M, Antonucci G, Manconi PE, Tositti G, Colangeli V, Lichtner M, Monforte Ad; ICoNA Study Group.

AIDS. 2007 Mar 12;21(5):599-606.

PMID:
17314522
20.

Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy.

Pol S, Vallet-Pichard A, Fontaine H.

J Viral Hepat. 2002 Jan;9(1):1-8. Review.

PMID:
11851897

Supplemental Content

Support Center